Sign in

    Penumbra Inc (PEN)

    Q4 2023 Earnings Summary

    Reported on Feb 19, 2025 (After Market Close)
    Pre-Earnings Price$262.68Last close (Feb 22, 2024)
    Post-Earnings Price$239.24Open (Feb 23, 2024)
    Price Change
    $-23.44(-8.92%)

    What went well

    • Penumbra is on track to achieving a gross margin of over 70%, demonstrating strong profitability potential while continuing to invest and scale its operations.
    • The company's U.S. thrombectomy business is projected to grow by 27% to 30% in 2024, driven by the success of their CAVT platform and new product launches, reflecting management's confidence in sustained growth. ,
    • Sustained momentum since late November has led to a notable uptick in Penumbra's trajectory, supported by an increase in new customers and ongoing dialogues with hospital systems and physicians, bolstering growth expectations for 2024.

    What went wrong

    • Penumbra expects its total international revenue in 2024 to be similar to 2023 levels, indicating a slowdown in international growth due to a focus on profitability rather than revenue expansion. This could impact overall top-line growth. , ,
    • The company's revenue growth guidance for 2024 is 16% to 20%, which represents a deceleration compared to previous years' growth rates. This slowdown raises concerns about Penumbra's ability to sustain its historical growth trajectory. , ,
    • In Q4 2023, Penumbra missed sell-side consensus revenue estimates for the first time since its IPO, which may suggest challenges in meeting market expectations and could affect investor confidence.

    Q&A Summary

    1. 2024 Growth Guidance
      Q: Why is 2024 growth guidance decelerating to 16%-20%?
      A: Management explains that while overall growth guidance is 16% to 20%, they are focusing on the U.S. thrombectomy business, projecting 27% to 30% growth in that segment ,. The deceleration in overall growth is due to factors like distributor order timing and a strategic focus on core thrombectomy products ,.

    2. Sales Cadence and Distributor Timing
      Q: How will sales cadence progress throughout 2024?
      A: Sales cadence will be consistent in the U.S., but international growth will vary due to distributor order timing and product launches ,. Distributor orders are not linear and can cause variability in quarterly results.

    3. International Growth and Profitability Focus
      Q: Why is international growth slowing, and are you discontinuing some products?
      A: Penumbra is reducing focus on less profitable international markets and discontinuing sales of certain products where reimbursement is insufficient ,. This strategic shift impacts international growth in 2024 as they concentrate on profitability.

    4. Thunderbolt Timeline
      Q: Is Thunderbolt's contribution pushed to 2026?
      A: Yes, revenue from Thunderbolt is not expected until 2026 ,. The trial is ongoing and enrolling well, but Thunderbolt revenue is not included in 2024 or 2025 guidance ,.

    5. Q4 Revenue Miss
      Q: Why did you miss Q4 revenue expectations?
      A: Despite being within guidance, Q4 revenue was slightly below consensus due to the timing of an uptick in trajectory that began in late November. Management remains confident due to the strong momentum going into 2024.

    6. Sales Force Expansion
      Q: How is the sales force expansion progressing?
      A: The majority of sales force hiring is complete, with new representatives ramping up quickly. There has been minimal churn among seasoned staff, and the expanded team is expected to support 2024 growth objectives.

    7. Guidance Philosophy
      Q: What is your approach to guidance this year?
      A: Management aims to provide guidance with more clarity and information, learning from last year's experience. They are not guiding aspirationally but basing projections on a better understanding of products and markets.

    8. Gross Margins and Profitability
      Q: Where are margins moving in the long term?
      A: Penumbra is on track to reach its longer-term target of 70%+ gross margin. They are scaling while continuing to invest, expecting favorable product mix to improve profitability.

    9. Flash 2.0 Enhancements
      Q: What are the enhancements in Flash 2.0?
      A: Flash 2.0 optimizes the advantages of CAVT by getting more clot out faster with even less blood loss.

    10. VAC Process and Customer Adoption
      Q: What is the status of VAC processes with Flash and Bolt?
      A: Penumbra has made significant progress through Value Analysis Committee processes, with many new customers starting to use the products. They are moving into a phase focusing on increasing physician adoption.

    11. International Reimbursement Challenges
      Q: Is the lack of reimbursement affecting international expansion?
      A: Reimbursement varies by country, and Penumbra needs to obtain appropriate reimbursement before launching products like CAVT in certain international markets.

    12. China Market Impact
      Q: Is China impacting distributor orders or market exits?
      A: Penumbra's unique revenue structure in China, including license fees and royalties, provides protection from current market challenges. They feel positive about their position and future opportunities in China.

    Related Publications